EPIRUS Biopharmaceuticals, Inc. (OTCMKTS:EPRSQ) Sees Large Decrease in Short Interest

EPIRUS Biopharmaceuticals, Inc. (OTCMKTS:EPRSQ) was the recipient of a significant drop in short interest during the month of December. As of December 31st, there was short interest totalling 9,800 shares, a drop of 86.6% from the December 15th total of 72,900 shares. Based on an average daily volume of 159,100 shares, the short-interest ratio is currently 0.1 days.

EPRSQ remained flat at $$0.01 during trading on Wednesday. The company had a trading volume of 172,901 shares, compared to its average volume of 96,927. EPIRUS Biopharmaceuticals has a 52-week low of $0.00 and a 52-week high of $0.02. The business has a fifty day simple moving average of $0.01.

EPIRUS Biopharmaceuticals Company Profile

EPIRUS Biopharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and commercializes biosimilar therapeutics worldwide. Its lead product candidate is BOW015, a biosimilar version of Remicade (infliximab) for the treatment of various inflammatory diseases. The company's pipeline of biosimilar product candidates also include BOW050, a biosimilar version of Humira (adalimumab) to treat inflammatory diseases, including rheumatoid arthritis and various other forms of adult and pediatric arthritis, ankylosing spondylitis, inflammatory bowel disease, and chronic psoriasis and psoriasis; and BOW070, a biosimilar version of Actemra (tocilizumab) for the treatment of rheumatoid arthritis, polyarticular arthritis, and systemic juvenile idiopathic arthritis.

Featured Article: NASDAQ

Receive News & Ratings for EPIRUS Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EPIRUS Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.